Wellmune WGP, from Biothera, significantly reduced upper respiratory tract infection symptoms in marathon runners while increasing vigor and overall health, according to a study published in the December issue of the Journal of Sports Science and Medicine. The double-blind, placebo-controlled study included 75 runners (35 men, 40 women) ages 18-53 (mean age 36 years) from the 2007 Carlsbad Marathon in California. During the four-week period following the marathon, subjects consumed Wellmune WGP.

The physical health results demonstrated a significant decrease in upper respiratory tract infection (URTI) symptoms at two and four weeks for subjects taking 250 mg of Wellmune WGP daily. The most common URTI symptoms reported were sore throat, stuffy or runny nose and cough. When asked how the supplement regimen was affecting their overall health, participants consuming 250 mg of Wellmune WGP daily reported 38% higher scores compared with the placebo group.

In addition, the Wellmune subjects reported significantly better scores on a variety of mood states, including a 22% increase in vigor (with 500 mg of Wellmune), 48% reduction in fatigue, 38% reduction in tension and a 38% reduction in confusion. The study employed a Profile of Mood States (POMS) questionnaire, a validated psychometric test that measures six mood states (vigor, fatigue, tension, confusion, depression and anger) using 65 adjective-based intensity scales. For further information: www.biothera.com